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Eﬃcacy and safety of intermittent preventive treatment 
with sulfadoxine-pyrimethamine for malaria in African 
infants: a pooled analysis of six randomised, 
placebo-controlled trials
John J Aponte, David Schellenberg, Andrea Egan, Alasdair Breckenridge, Ilona Carneiro, Julia Critchley, Ina Danquah, Alexander Dodoo, 
Robin Kobbe, Bertrand Lell, Jürgen May, Zul Premji, Sergi Sanz, Esperanza Sevene, Rachida Soulaymani-Becheikh, Peter Winstanley, Samuel Adjei, 
Sylvester Anemana, Daniel Chandramohan, Saadou Issifou, Frank Mockenhaupt, Seth Owusu-Agyei, Brian Greenwood, Martin P Grobusch, 
Peter G Kremsner, Eusebio Macete, Hassan Mshinda, Robert D Newman, Laurence Slutsker, Marcel Tanner, Pedro Alonso, Clara Menendez
Summary 
Background Intermittent preventive treatment (IPT) is a promising strategy for malaria control in infants. We 
undertook a pooled analysis of the safety and eﬃcacy of IPT with sulfadoxine-pyrimethamine in African infants.
Methods We pooled data from six double-blind, randomised, placebo-controlled trials (undertaken one each in 
Tanzania, Mozambique, and Gabon, and three in Ghana) that assessed the eﬃcacy of IPT with sulfadoxine-
pyrimethamine in children. In all trials, IPT or placebo was given to children at the time of routine vaccinations 
delivered by WHO’s Expanded Program on Immunization. Data from the trials for incidence of clinical malaria, risk 
of anaemia (packed-cell volume <25% or haemoglobin <80 g/L [A: converted to SI units, ok?]), and incidence of 
hospital admissions and adverse events in infants up to 12 months of age were reanalysed by use of standard outcome 
deﬁnitions and time periods [A: ok?]. Analysis was by modiﬁed intention to treat, including all infants who received 
at least one dose of IPT or placebo. [A: please check that all edits in this section are correct]
Findings The six trials provided data on 7930 infants (IPT, n=3958; placebo, n=3972). IPT had a protective eﬃcacy of 
30·3% (95% CI 19·8–39·4, p<0·0001) against clinical malaria, 21·3% (8·2–32·5, p=0·002) against the risk of anaemia, 
38·1% (12·5–56·2, p=0·007) against hospital admissions associated with malaria parasitaemia, and 22·9% (10·0–34·0, 
p=0·001) against all-cause hospital admissions. [A: edit ok?] There were 56 deaths in the ITP group compared with 
53 in the placebo group (rate ratio 1·05, 95% CI 0·72–1·54, p=0·79). One death was judged possibly related to study 
treatment (IPT group). Four of 676 non-fatal hospital admissions in the IPT group were deemed related to study 
treatment compared with ﬁve of 860 in the placebo group. None of three serious dermatological adverse events in the 
IPT group were judged related to study treatment compared with one of 13 in the placebo group. [A: edits ok?]
Interpretation IPT with sulfadoxine-pyrimethamine in infants was safe and eﬃcacious across a range of malaria 
transmission settings, suggesting that this intervention is a useful contribution to malaria control.
Funding Bill & Melinda Gates Foundation.
Introduction
Plasmodium falciparum malaria is a major cause of 
disease and death in children in sub-Saharan Africa, and 
improved control measures are urgently needed. 
Intermittent preventive treatment (IPT) is the 
administration of a full course of an antimalarial drug at 
speciﬁed timepoints, whether or not parasites are 
present. Previous studies have shown that continuous 
chemoprophylaxis in infants reduces morbidity and 
mortality caused by malaria. However, this approach has 
not been implemented in endemic countries because of 
the major logistical challenges involved and fears that 
large-scale drug use would hasten the spread of drug 
resistance and impair the development of naturally 
acquired antimalarial immunity.1–5 Since IPT in infants is 
associated with lower drug exposure than is 
chemoprophylaxis, the eﬀect of IPT on the spread of 
resistance and impairment of the development of 
immunity might also be lower. Furthermore, logistical 
challenges could be reduced by giving IPT to infants at 
the time of routine vaccinations delivered through 
WHO’s Expanded Program on Immunization (EPI).
Sulfadoxine-pyrimethamine [A: Our house style is not 
to abbreviate drug names] could be useful for IPT in 
infants because this combination is available, aﬀordable, 
well tolerated, and already recommended for IPT in 
pregnancy.6,7 The long half-life of sulfadoxine-
pyrimethamine could produce an extended prophylactic 
eﬀect and enables the combination to be given as a single 
dose, which can be supervised. From 1999 to 2007, six 
randomised, placebo-controlled trials of IPT with 
sulfadoxine-pyrimethamine were completed.8–13 These 
trials assessed the eﬀect of three or four doses of IPT on 
malaria in early childhood. Since the study designs 
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diﬀered in terms of dosing schedule, primary endpoints, 
and duration of follow-up, we were unable to compare 
the trials using the published results. We therefore 
reanalysed the data using standardised outcome 
deﬁnitions and time periods to generate a meaningful 
pooled analysis of the safety and eﬃcacy of IPT given to 
infants at the time of routine immunisation. We also 
investigated whether there was a potential increase in 
morbidity in the period after the intervention.
Methods
[A: please note, subheadings changed to conform with 
Lancet style]
Search strategy and selection criteria
This analysis was led by the IPTi Consortium, made up 
of autonomous research institutions, WHO, and 
UNICEF, and assembled to assess IPT in infants as a 
potential public health tool.14–16 [A: URL corrected, ok?]] 
An independent consortium safety panel and a statistical 
working group (webappendix) were convened to under-
take pooled analyses of safety and eﬃcacy, respectively. 
In 2005, the IPTi Consortium invited the principal 
investigator of every completed or continuing trial of IPT 
with sulfadoxine-pyrimethamine in infants to take part 
in the pooled analyses. Trials were eligible for inclusion if 
they had randomly assigned asymptomatic children 
(younger than 1 year) who were attending routine health 
contacts to either IPT with sulfadoxine-pyrimethamine 
or placebo. [A: edit ok? Placebo had not been mentioned] 
We did not include trials of intermittent treatment that 
used diﬀerent drugs, did not deliver IPT alongside EPI 
vaccinations, used IPT as a treatment for anaemia, or 
gave IPT at monthly intervals to schoolchildren or 
children less than 10 years of age in settings with highly 
seasonal transmission of malaria. These pooled analyses 
include all six eligible trials of IPT with sulfadoxine-
pyrimethamine in infants published up to May, 2009.8–13 
A PubMed search for randomised controlled trials of 
infants 1–23 months old with the key words “intermittent“, 
“treatment“, “malaria“, and “infants” did not ﬁnd any 
additional studies that met our eligibility criteria.
Patients, study design, and procedures
The six randomised controlled trials, described in detail 
elsewhere, are summarised in table 1 and ﬁgure 1. [A: 
references have been renumbered so that they appear in 
order of mention in table 1. Please check throughout 
carefully] The trials were undertaken in Ifakara in 
Tanzania, Manhiça in Mozambique, Lambaréné in 
Gabon, and Navrongo, Kumasi, and Tamale, in Ghana, 
and assessed the eﬃcacy of IPT with sulfadoxine-
pyrimethamine for prevention of clinical malaria and 
anaemia during the ﬁrst or second year of life, or both. 
Block randomisation by individual was done in all trials 
apart from the one in Navrongo, which was cluster-
randomised by community. All trials were double-blind. 
[A: ok?]
The dosing schedule for IPT and placebo diﬀered 
between the trials (ﬁgure 1). Doses of IPT were given 
according to bodyweight in the trials in Ifakara and 
Manhiça, according to dose number in the trial in 
Navrongo, and as a ﬁxed dose in the trials in Kumasi, 
Lambaréné, and Tamale. One tablet contained 500 mg 
sulfadoxine and 25 mg pyrimethamine. All six trials had 
received ethical approval.
Safety and eﬃcacy were assessed by passive clinical 
surveillance in all trials. Additionally, active detection of 
malaria and anaemia was done every month in the trials 
in Lambaréné and Kumasi, and every 3 months in the 
trial in Tamale (ﬁgure 1); in Lambaréné, a blood sample 
was taken only if the child was febrile, whereas in 
Kumasi and Tamale, the sample was taken irrespective 
of the presence of symptoms. In the trial in Lambaréné, 
safety was reviewed 1 week after every dose; a blood 
sample was taken if the child was febrile. In the trial in 
Manhiça, safety assessment was enhanced by home 
visits 1 week after every dose, registration of 
dermatological complaints of children attending a health 
facility, and blood tests 1 month after the second dose of 
IPT or placebo [A: ok?]. In the trial in Navrongo, 20% of 
infants were visited within 4 weeks of IPT or placebo 
administration so that side-eﬀects could be assessed.
Thick blood ﬁlms were stained and read by use of 
standard procedures. Parasite density was calculated on 
the assumption of a mean [A: ok? Since average can 
mean medium or mean] of 8000 leucocytes per µL in all 
trials, apart from the one in Lambaréné, where a volume-
based method was used.17
The presence of anaemia was determined by packed-
cell volume measured in microcapillary tubes in the trials 
in Ifakara, Navrongo, and Manhiça, and by haemoglobin 
concentration measured with a HemoCue photometer in 
the trials in Kumasi (HemoCue, Derbyshire, UK) and 
Tamale (HemoCue, Angelholm, Sweden). In the trial in 
Lambaréné, full blood counts were undertaken on an 
Abbott Cell-Dyn 3000 device (Abbott Diagnostics, Santa 
Clara, CA, USA). There is no accepted common deﬁnition 
of anaemia in children under 6 months of age; therefore, 
a cut-oﬀ that was common among trials was used 
(packed-cell volume <25% or haemoglobin <80 g/L).
Statistical analysis
An analytical plan was agreed by all investigators before 
the reanalysis started. Data were reanalysed at the 
individual level. To enable a pooled analysis, outcome and 
follow-up deﬁnitions were based on information common 
to all trials; therefore, results do not necessarily correspond 
with those in reports published for each study. Analysis 
was by modiﬁed intention to treat, including all children 
who received at least one dose of IPT or placebo up to the 
follow-up times deﬁned in table 2. We examined the eﬀect 
of the IPT intervention during the 35 days after a dose to 
assess the prophylactic beneﬁt of sulfadoxine-
pyrimethamine. We chose this interval because, according 
For more on the 
IPTi Consortium see http://
www.ipti-malaria.org/
See Online for webappendix
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to the elimination half-life reported by the manufacturer, 
residual sulfadoxine plasma concentrations after 5 weeks 
are less than 5%, which is consistent with negligible 
inhibitory activity.18 [A: please mention that the potential 
rebound eﬀect was examined, and why]
Negative binomial regression, which allows for potential 
clustering of episodes within individuals, was used to 
investigate the eﬀect of IPT on the incidence of all 
episodes of clinical malaria, clinical malaria with a locally 
sensitive case deﬁnition,19 all-cause hospital admissions, 
and hospital admissions associated with microscopically 
conﬁrmed [A: correct?] malaria parasitaemia. To allow for 
clustering across individuals within the trial in Navrongo, 
robust SEs were used. Incidence was calculated as the 
number of episodes divided by the time at risk (for 
deﬁnitions see table 2). [A:is this ok to add here?] Infants 
were not deemed at risk for 21 days after a clinical malaria 
episode, hospital admission, or receipt of an antimalarial 
treatment. This 21-day period was selected to avoid overlap 
with the 28-day period for active detection visits in the 
trials in Kumasi and Lambaréné. The eﬀect of IPT on the 
relative risk of at least one episode of anaemia, with as the 
denominator the number of children at risk from the ﬁrst 
dose until 12 months of age, was analysed by use of a 
Poisson regression model, with log-link and a robust 
error variance.20
The eﬃcacy of IPT was deﬁned as (1–RR)×100, where 
RR is the relative rate or relative risk [A: since relative 
risk can mean rate ratio or risk ratio, please deﬁne which 
is used]. Combined estimates were obtained by meta-
Ifakara8 Navrongo9 Manhiça10 Kumasi11 Tamale12 Lambaréné13
Country Tanzania Ghana Mozambique Ghana Ghana Gabon
Recruitment years 1999–2000 2000–02 2002–04 2003–05 2003 2002–04
Pattern of malaria transmission Perennial Highly seasonal Perennial with seasonal peaks Perennial with seasonal 
peaks
Perennial with 
seasonal peaks
Perennial with 
seasonal peaks
Insecticide-treated bednet use in trial 
participants (n/N [%]) [A1]
nn/NN (67%) nn/NN (18%) nn/NN (0%) nn/NN (2%)* nn/NN (3%)† nn/NN (5%)
Oﬃcial ﬁrst-line treatment for 
uncomplicated malaria
Chloroquine or sulfadoxine-
pyrimethamine
Chloroquine Chloroquine and sulfadoxine-
pyrimethamine
Chloroquine Chloroquine Chloroquine
Actual drug used in trial [A: ok?] for 
treatment of uncomplicated malaria
Sulfadoxine-pyrimethamine Chloroquine Quinine Amodiaquine and 
artesunate
Artesunate Amodiaquine 
and artesunate
Sulfadoxine-pyrimethamine in-vivo 
failure at 14 days in symptomatic 
6–59-month old children (% [date 
assessed] [A: ok?])
31% (1999–2000) 22% (2004) 21% (2001) Not available 14% (2002) 21% (2004)
Iron supplementation Unsupervised Unsupervised None None None None
HIV prevalence (not measured in trial 
participants or their mothers, %)
6% in ANCs in Ifakara About 2% in ANCs 23% in ANCs in Manhiça 2·7% in ANCs About 2–3% in 
ANCs
7·5% [A: in 
which 
population?]
Randomisation Individual Cluster Individual Individual Individual Individual
Dose of IPT with sulfadoxine-
pyrimethamine‡
According to bodyweight 
(<5 kg, quarter of a tablet; 
5–10 kg, half a tablet; >10 kg, 
one tablet)
According to dose number 
(half a tablet for ﬁrst and 
second doses, one tablet for 
third and fourth doses)
According to bodyweight 
(<5 kg, quarter of a tablet; 
5–10 kg, half a tablet; >10 kg, 
one tablet)
Fixed (half a tablet at 
each dose)
Fixed (half a 
tablet at each 
dose)
Fixed (half a 
tablet at each 
dose)
Passive case detection Yes Yes Yes Yes Yes Yes
Active case detection No No No Monthly Every 
3 months
Monthly
Number of children (modiﬁed 
ITT population)§ [A1]
IPT 350 1221 748 535 600 504
Placebo 351 1225 755 535 599 507
Incidence of clinical malaria 
(episodes per person-years at risk)¶
0·54 1·10 0·79 1·27 0·95 0·16
Risk of anaemia (of the ﬁrst or only 
episode, %)||
8·6% 6·3% 10·6% 37·6% 31·7% 15·7%
ANC=antenatal clinic. IPT=intermittent preventive treatment. ITT=intention-to-treat. *According to Ghana Demographic and Health Survey, 2003. †Bednet use in 2001 in trial area—not necessarily 
insecticide-treated nets. ‡Manufacturer of sulfadoxine-pyrimethamine and placebo was La Roche ([A: town, country?]) in all trials apart from the one in Navrongo, where it was Cosmos Pharmaceuticals 
(A: town?], Nairobi). §Modiﬁed ITT population includes all children who received at least one dose of study drug. [A1: is this ok? ie, the ITT population, rather than the total number of children in the trials?] 
¶In the placebo group, from ﬁrst dose until 12 months of age; history of fever or measured fever with any Plasmodium falciparum parasitaemia. History of fever included reported fever during the past 24 h in 
the trials in Ifakara and Manhiça, and during the past 48 h for the other four trials. Measured fever was deﬁned as an axillary temperature 37·5°C or more for trials in Ifakara, Navrongo, Tamale, and Manhiça; 
rectal or tympanic temperature 38°C or more for the trial in Kumasi, and 38·5°C or more for the trial in Lambaréné. ||In the placebo group, from ﬁrst dose until 12 months of age; packed-cell volume less than 25% 
in trials in Ifakara, Navrongo, and Manhiça, and a haemoglobin concentration less than 80 g/L in the trials in Kumasi, Lambaréné, and Tamale. [A1: please provide numerators and denominators to 
accompany %s for ITN use] 
Table 1: Characteristics of six trials of IPT with sulfadoxine-pyrimethamine versus placebo in infants
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analysis with random eﬀects, and as weight for each trial 
the inverse of the SE of the estimated RR in the 
logarithmic scale. To assess the eﬀect of an individual 
trial in the meta-analysis, sensitivity analyses were done 
in which one study at a time was removed from the 
analysis. Analyses were done with Stata version xx 
software. [A: version number?]
Standard WHO deﬁnitions were used for adverse 
events and for the grading of severity.21 In all trials apart 
from the one in Kumasi, a serious adverse event was 
deﬁned as a hospital admission or death. In the trial in 
Kumasi, a life-threatening event or enduring disability 
was also judged as a serious adverse event (in the other 
trials, a patient with a life-threatening event would be 
admitted to hospital [A: edit ok?]). Assessment of causality 
was made by the on-site principal investigator or 
physician. Causality was assessed on symptoms known 
to be related to sulfadoxine-pyrimethamine, apart from 
in the trial in Kumasi where all adverse events that 
occurred within 8 weeks of treatment were deemed 
possibly related to study drug. Serious adverse events 
that occurred more than 3 months after the last dose of 
study drug were deemed very unlikely to be related to 
treatment and excluded from these analyses.
The number of deaths, non-fatal hospital admissions, 
serious dermatological adverse events [A: why were only 
dermatological adverse events analysed?], total sample 
size, and person-time at risk were extracted by principal 
investigators or statisticians and reviewed by the 
consortium safety panel. A meta-analysis was done on 
the risk of mortality by use of Review Manager version 
5.0 or StatsDirect version 2.7.1 software. The numerator 
was the number of deaths, and the denominator was the 
number of infants who received at least one dose of IPT 
or placebo [A: ok?]. The pooled rate ratio was calculated 
by the DerSimonian-Laird method. For the trial that was 
cluster randomised, the rate ratio and SE of the rate ratio 
were estimated by use of a robust cluster method. The 
cluster-adjusted SE was identical to the unadjusted SE.
Heterogeneity between trials was assessed by visual 
inspection of forest plots of the eﬀects and 95% CIs for 
each site, calculation of a χ² test for heterogeneity 
(statistical signiﬁcance at 10% level), and calculation of 
the I² statistic (which quantiﬁes the amount of hetero-
geneity over and above that expected due to chance alone 
on a scale from 0% to 100%).22 Fixed-eﬀect meta-analysis 
was used to pool data for this outcome measure. 
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁnal 
responsibility for the decision to submit for publication.
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A cross-sectional or active case detection visit
Figure 1: Schedules of study treatment and follow-up visits
Vertical bars represent the age when intermittent preventive treatment with sulfadoxine-pyrimethamine or 
placebo was given (and number of dose). *Follow-up in the trial in Lambaréné was up to 30 months of age.
Start of time at risk End of time at risk
Eﬃcacy (clinical malaria, hospital admissions, anaemia)
Primary Dose 1 of IPT or placebo 12 months of age
Secondary Dose 1 of IPT or placebo 3 months after the last dose of IPT or placebo
Prophylactic eﬀect I Dose of IPT or placebo at 3 months of age* 35 days after start of time at risk
Prophylactic eﬀect II Dose of IPT or placebo at 9 months of age† 35 days after start of time at risk
Prophylactic eﬀect III Dose of IPT or placebo at 12 months or 15 months of age‡ 35 days after start of time at risk
Inter-dose eﬀect 35 days after the dose of IPT or placebo at 3 or 4 months of age Dose of IPT or placebo at 9 months of age
Potential rebound I 35 days after the dose of IPT or placebo at 9 months of age 15 months of age or the next dose of IPT or placebo§
Potential rebound II 35 days after the last dose of IPT or placebo¶ 5 months after start of time at risk
Safety (deaths, adverse eﬀects)
Primary Dose 1 of IPT or placebo 3 months after the last dose given or 12 months of age
IPT=intermittent preventive treatment. * Dose 2 in the trial in Ifakara, dose 1 in the other trials. †Dose 3 in the trials in Ifakara, Navrongo, and Manhiça; dose 2 in the trials in 
Kumasi, Tamale, and Lambaréné. ‡Dose 4 in the trial in Navrongo at 12 months; dose 3 in the trials in Kumasi, Tamale, and Lambaréné at 15 months of age. §Next dose at 
12 months of age in the trial in Navrongo, and 15 months of age in the trials in Kumasi, Tamale, and Lambaréné. ¶Last dose was at 9 months of age in the trials in Ifakara and 
Manhiça, at 12 months of age in the trial in Navrongo, and at 15 months of age in the trials in Kumasi, Tamale, and Lambaréné. [A: “or placebo” added to all—ok?]
Table 2: Risk periods for each analysis
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Results
[A: to conform with journal style, subheadings have been 
deleted from this section. Also, to avoid repetition, any 
data in the text that is clearly shown in the tables and 
ﬁgures has been deleted]
This analysis is based on data from 7930 infants (IPT, 
n=3958; placebo, n=3972) in all six trials of IPT with 
sulfadoxine-pyrimethamine in infants published up to 
May, 2009. Reported baseline characteristics were similar 
between IPT and placebo groups in all the trials. [A: 
please provide a table showing the baseline characteristics 
of the two groups]
Table 3 shows the estimates of eﬃcacy of IPT in infants 
up to 12 months of age in the individual trials. The 
combined estimate of protective eﬃcacy against the 
primary deﬁnition of clinical malaria in children aged up 
to 12 months was 30·3% (95% CI 19·8–39·4, p<0.0001; 
ﬁgure 2 and table 4). There was signiﬁcant heterogeneity 
between trials (I²=61·8%). Removal of the trial with the 
highest protective eﬃcacy (Ifakara) reduced heterogeneity 
to non-signiﬁcant levels, and the combined eﬃcacy 
estimate to 25·9% (19·6–31·7%, p<0·001; table 4). 
[A: please provide exact p value unless p<0·0001] Detailed 
information about each analysis, including the total 
number of events and person-years at risk, total number 
of children in each site and outcome, as well as other 
analyses are provided in the webappendix.
The eﬀect of IPT on the relative risk of anaemia in 
infants ranged from 5·4% to 49·9%, with moderate 
heterogeneity between trials (I²=46·9%). The combined 
eﬃcacy estimate for risk of anaemia was 21·3% 
(8·2–32·5, p=0·002; table 4).
IPT had protective eﬃcacies of 22·9% (10·0–34·0, 
p=0·001) against all-cause hospital admissions and 
38·1% (12·5–56·2, p=0·007) and for hospital admissions 
associated with malaria parasitaemia (table 4). The 
heterogeneity between trials for these two outcomes was 
moderate (I²=33·5% and 49·6%, respectively); however, 
removing the trial with the highest protective eﬃcacy 
made little diﬀerence to the estimates (table 4).
Ifakara8 Navrongo9 Manhiça10 Kumasi11 Tamale12 Lambaréné13
From dose 1 until 12 months of age
Clinical malaria
Primary deﬁnition* 59·4% (41·7 to 71·7) 30·3% (17·8 to 40·9) 20·8% (3·5 to 35·0) 20·7% (8·7 to 31·2) 32·4% (19·6 to 43·2) 22·6% (–24·2 to 51·7)
Locally deﬁned cut-oﬀ density† 61·9% (43·5 to 74·3) 32·3% (16·9 to 44·8) 30·9% (14·4 to 44·3) 22·7% (9·2 to 34·1) 27·4% (4·7 to 44·6) 29·2% (–15·1 to 56·5)
High-density cut-oﬀ‡ 56·3% (25·3 to 74·5) 33·2% (14·0 to 48·1) 26·6% (6·5 to 42·4) 18·4% (–15·1 to 42·2) 26·0% (–22·0 to 55·1) 26·2% (–49·0 to 63·5)
All-cause hospital admissions 29·0% (6·6 to 46·1) 18·3% (0·3 to 33·1) 24·9% (6·6 to 39·7) 17·8% (–22·5 to 44·8) 49·8% (18·5 to 69·0) –35·8% (–142·3 to 23·9)
Hospital admissions associated 
with malaria parasitaemia§
58·3% (28·4 to 75·8) 52·1% (29·5 to 67·5) 20·3% (–19·9 to 47·0) –6·6% (–103·1 to 44·1) 44·5% (–80·1 to 82·9) ··
Anaemia (reduced risk of ﬁrst or 
only episode)¶
49·9% (8·4 to 72·5) 46·5% (21·2 to 63·7) 5·4% (–27·5 to 29·8) 11·1% (–4·5 to 24·4) 17·0% (0·8 to 30·5) 25·2% (–2·7 to 45·5)
Against clinical malaria (primary deﬁnition) on diﬀerent follow-up times
Prophylactic eﬀect||
I (after dose at 3 months of age) 77·7% (–3·0 to 95·2) 75·6% (49·6 to 88·2) 57·5% (20·6 to 77·3) 82·0% (61·8 to 91·5) 83·0% (12·8 to 96·7) 74·8% (–125·5 to 97·2)
II (after dose at 9 months of age) 91·1% (62·1 to 97·9) 79·3% (69·5 to 85·9) 65·2% (37·1 to 80·7) 47·6% (17·1 to 66·8) 97·6% (90·5 to 99·4) 72·9% (–53·2 to 95·2)
III (after dose at 12 or 15 months 
of age)
·· 73·7% (57·6 to 83·7) ·· 29·7% (–5·1 to 52·9) 90·6% (79·7 to 95·6) 77·5% (–100·9 to 97·5)
Inter-dose eﬀect period** 42·4% (–1·2 to 67·3) 12·9% (–6·8 to 29·0) –8·0% (–39·3 to 16·3) 11·5% (–6·1 to 26·2) 19·6% (–0·2 to 35·5) 11·2% (–62·9 to 51·6)
Potential rebound period I†† 29·0% (–4·2 to 51·6) –3·4% (–29·3 to 17·5) 7·4% (–13·4 to 24·4) 7·8% (–9·1 to 22·1) 19·6% (–2·2 to 36·7) 12·7% (–54·9 to 50·8)
Potential rebound period II‡‡
Clinical malaria (primary deﬁnition) 30·3% (1·0 to 50·9) 0·2% (–20·3 to 17·1) –11·0% (–45·0 to 15·0) –5·8% (–24·0 to 9·8) –0·3% (–18·9 to 15·4) –36·3% (–147·3 to 24·9)
All-cause hospital admissions –7·9% (–51·9 to 23·4) –16·5% (–54·0 to 11·9) 8·4% (–25·6 to 33·2) –19·8% (–108·0 to 31·0) 24·6% (–21·5 to 53·3) –1·4% (–115·7 to 52·3)
Hospital admissions associated 
with malaria parasitaemia
11·3% (–74·4 to 54·9) –8·6% (–79·5 to 34·3) –36·1% (–117·4 to 14·8) –47·7% (–261·2 to 39·6) –74·5% (–496·1 to 48·9) ··
Anaemia (reduced risk of ﬁrst or 
only episode)
40·0% (–11·8 to 67·8) –24·2% (–105·0 to 26·3) 10·8% (–36·4 to 41·7) –2·5% (–22·9 to 14·6) 3·4% (–9·9 to 15·1) –15·1% (–154·3 to 47·9)
··=data not available. IPT=intermittent preventive treatment. Data are % protective eﬃcacy (95% CI). Protective eﬃcacy deﬁned as (1–RR)×100. [A: ok?] *Primary deﬁnition: history of fever or measured fever 
with any P falciparum parasitaemia. History of fever included reported fever during the past 24 h in the trials in Ifakara and Manhiça, and during the past 48 h for the other four trials. Measured fever was deﬁned 
as an axillary temperature 37·5°C or more for the trials in Ifakara, Navrongo, Tamale, and Manhiça; rectal or tympanic temperature 38°C or more for the trial in Kumasi, and 38·5°C or more for the trail in 
Lambaréné. †A history of fever, or measured fever, with a minimum P falciparum parasite density for each site chosen to have a speciﬁcity more than 90%; trials in Ifakara, Manhiça, and Kumasi more than 
500 parasites per µL; trial in Lambaréné more than 600 parasites per µL; trial in Tamale more than 5000 parasites per µL; trial in Navrongo more than 8000 parasites per µL. ‡Episodes with a history of fever or 
measured fever with P falciparum parasitaemia more than 20 000 parasites per µL. §Admissions to a paediatric ward with any P falciparum parasitaemia irrespective of symptoms suggestive of malaria or a clinical 
diagnosis of malaria. ¶Packed-cell volume less than 25% in the trials in Ifakara, Navrongo, and Manhiça, and a haemoglobin concentration less than 80 g/L in the trials in Kumasi, Lambaréné, and Tamale. ||See 
table 2 for deﬁnitions. **From 35 days after dose at 3 months or 4 months of age until dose at 9 months of age. ††From 35 days after the dose at 9 months of age up to the next dose of IPT or age 
15 months. ‡‡5-month period starting 35 days after last dose. [A: please check all footnotes are cited correctly]
Table 3: Protective eﬃcacies of IPT with sulfadoxine-pyrimethamine in infants
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Prophylactic eﬀects I, II, and III are the 35-day intervals 
following the doses at 3 months, 9 months, and 12 or 
15 months of age, respectively. During prophylactic eﬀect 
I, the incidence of clinical malaria was between 57·5% 
and 83·0% lower in the IPT group than in the placebo 
group [A: is this edit correct—ie, these were the % 
diﬀerences?] (table 3). Malaria incidence was 47·6–97·6% 
and 29·7–90·6% lower in the ITP group than in the 
placebo group during prophylactic eﬀects II and III, 
respectively. [A: is this edit correct?] Analyses of the inter-
dose eﬀect (35 days after the IPT or placebo dose at 3 or 
4 months of age until the dose at 9 months of age) varied 
between trials with borderline signiﬁcant eﬃcacy in the 
trials in Ifakara and Tamale, but no eﬀect was seen in the 
other trials. 
Incidence of clinical malaria and hospital admissions 
and the risk of anaemia did not diﬀer between groups in 
either of the potential rebound periods (tables 3 and 4, 
see table 2 for deﬁnitions). [A: edit ok?] Similar results 
were found in the sensitivity analysis (table 4).
There were 56 deaths (1·4%) in the IPT group compared 
with 53 (1·3%) in the placebo group (rate ratio 1·05, 95% 
CI 0·72–1·54, p=0·79). There was moderate statistical 
heterogeneity in the number of deaths between trials 
(I²=24·6%). One death, in the IPT group of the trial in 
Kumasi, was classiﬁed as possibly caused by study 
treatment [A: ok, rather than IPT? Were assignment 
groups still masked when classiﬁed?], since it occurred 
19 days after a treatment dose (table 5). At the visit after 
administration of the second dose at 9 months of age, 
malaria was conﬁrmed by microscopy and the infant 
received amodiaquine, and iron and folic acid 
supplementation. 2 weeks later, the infant became very 
weak, was admitted to hospital, given a blood transfusion 
for severe anaemia, and received penicillin, artesunate, 
paracetamol, iron, and folic acid. The infant was 
discharged 6 days later in an apparently satisfactory 
condition but died the next night at home. The most 
probable cause of death was sepsis with complications of 
recent malaria and severe anaemia.
Four of 676 non-fatal hospital admissions in the IPT 
group were deemed related to study treatment (assigned 
while the trials were masked), compared with ﬁve of 
860 in the placebo group. [A: edit ok?] In the trial in 
Kumasi, causality could not be assessed for ﬁve hospital 
admissions (IPT, n=3; placebo, n=2) because hospital 
ﬁles were missing.
Three serious dermatological adverse events were 
reported in the IPT group; however, none of these was 
judged related to study treatment (table 5). Of 13 serious 
dermatological adverse events in the placebo group, one 
was classiﬁed as possibly related to study drug, since it 
occurred within 3 weeks after a dose. At the time of the 
second dose of study treatment at 9 months of age, the 
infant had malaria and received artesunate-amodiaquine 
(in addition to study treatment) but was not admitted to 
hospital. The infant developed bullous skin lesions 
3 weeks later. Another infant in the placebo group was 
diagnosed with Stevens–Johnson syndrome and died at 
the age of 5 months from multiple organ failure, 
2 months after the ﬁrst dose of study treatment. The 
infant was HIV-positive and had been started on agents 
known to be associated with Stevens–Johnson syndrome 
(antituberculosis drugs [isoniazid, rifampicin, 
pyrazinamide, and ethambutol] and co-trimoxazole) 
5 days before the onset of dermatological symptoms. The 
child had not been admitted to hospital.
Discussion
[A: any repetition of Introduction and Results sections 
has been deleted] This pooled analysis of six randomised, 
placebo-controlled trials showed that the incidence of 
clinical malaria and hospital admissions and the risk of 
anaemia were lower in infants assigned to ITP with 
sulfadoxine-pyrimethamine than in those assigned to 
placebo. Other trials of intermittent treatment were not 
included in this analysis because they used diﬀerent 
drugs and did not deliver IPT at the same time as EPI 
vaccines,23 used IPT as a treatment for anaemia in 
children,24,25 or gave IPT with monthly intervals to 
schoolchildren26 or children up to 5 years or 10 years of 
age in settings with highly seasonal transmission of 
malaria.27–29 [A: edit ok (ie, were the schoolchildren in ref 
26 given IPT at monthly intervals)?]
None of the individual trials had suﬃcient power to 
assess the eﬀect of IPT on mortality. However, our meta-
analysis found that the overall number of deaths did not 
diﬀer between groups, suggesting that IPT does not 
reduce mortality compared with placebo. All the studies 
provided study participants with good access to curative 
services, which, combined with intensive follow-up in 
some studies, might account for the low crude mortality 
rates recorded in the trials. Our eﬃcacy estimates might 
therefore underestimate the potential eﬀect of IPT on 
Ifakara
Navrongo
Manhiça
Kumasi
Tamale
Lambaréné
Overal protective eﬃcacy
59·4 (41·7 to 71·7)
30·3 (17·8 to 40·9)
20·8 (3·5 to 35·0)
20·7 (8·7 to 31·2)
32·4 (19·6 to 43·2)
22·6 (–24·2 to 51·7)
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6·8
100·0
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Figure 2: Combined estimates for the protective eﬃcacy of IPT with sulfadoxine-pyrimethamine in infants 
against clinical malaria from dose 1 up to 12 months of age
The width of the diamond represents the 95% CI interval in the overall pooled protective eﬃcacy estimate. 
[A: vertical line moved to 0%. Ok?]
15
10
15
20
25
30
35
40
45
50
55
Articles
www.thelancet.com   Vol 374 7
mortality in populations with poor access to curative 
health services. Although IPT did not aﬀect mortality 
rates, it was associated with a reduced incidence of illness 
suﬃciently severe to warrant hospital admission, 
reﬂecting a potential of IPT to save lives. A pooled 
analysis of safety and eﬃcacy at 3 months after the last 
dose given (ie, including doses given between 12 months 
and 24 months) in four of the six trials showed similar 
safety and eﬃcacy outcomes to the analysis at 12 months 
of age.  
Careful assessment of safety is important when 
preventive interventions are being evaluated, since those 
given to healthy individuals need to have very high 
beneﬁt-to-harm ratios. None of the serious dermatological 
adverse events in the IPT group was associated with 
study treatment. However, there was one suspected case 
Placebo IPT Combined estimates Sensitivity analysis§
Events PYAR* Incidence 
per PYAR
Events PYAR* Incidence 
per PYAR
Pooled estimate of 
protective eﬃcacy† 
(% [95% CI])
I2‡ p value Pooled estimate of 
protective eﬃcacy† 
(% [95% CI])
p value Trial removed
From dose 1 until 12 months of age
Clinical malaria
Primary deﬁnition¶ 2257 2598 0·87 1658 2625 0·63 30·3% (19·8 to 39·4) 61·8 <0·0001 25·9% (19·6, 31·7) ?? Ifakara8
Locally deﬁned cut-
oﬀ density||
1473 2632 0·56 1048 2651 0·40 32·9% (21·8 to 42·4) 53·7 ?? 27·7% (20·2 to 34·5) ?? Ifakara8
High-density cut-oﬀ** 656 2671 0·25 467 2684 0·17 29·9% (19·3 to 39·1) 0 ?? 27·4% (16·1 to 37·3) ?? Ifakara8
All-cause hospital 
admissions
898 2776 0·32 714 2783 0·26 22·9% (10·0 to 34·0) 33·5 0·001 20·6% (9·8 to 30·1) ?? Tamale12
Hospital admissions 
associated with malaria 
parasitaemia††
233 2477 0·09 141 2480 0·06 38·1% (12·5 to 56·2) 49·6 0·007 31·4% (–0·4 to 53·1) ?? Ifakara8
Anaemia (reduced risk of 
ﬁrst or only episode)‡‡
656 3963 0·17 526 3948 0·13 21·3% (8·2 to 32·5) 46·9 0·002 18·7% (6·2 to 29·5) ?? Ifakara8
Against clinical malaria (primary deﬁnition) on diﬀerent follow-up times
Prophylactic eﬀect§§
I (after dose at 
3 months of age)
152 341 0·45 42 344 0·12 73·1% (60·9 to 81·4) 0 ?? 72·4% (59·6 to 81·2) ?? Tamale12
II (after dose at 
9 months of age)
309 307 1·00 87 323 0·27 79·7% (60·1 to 89·7) 79·8 ?? 71·3% (51·0 to 83·2) ?? Tamale12
III (after dose at 12 or 
15 months of age)
237 207 1·14 95 224 0·42 73·5% (31·3 to 89·8) 87·6 ?? 59·8% (5·4 to 82·9) ?? Tamale12
Inter-dose eﬀect 
period¶¶
1185 1294 0·92 1054 1298 0·81 12·1% (2·2 to 21·0) 5·7 ?? 10·8% (1·1 to 19·6) ?? Ifakara8
Potential rebound 
period I||||
1264 1405 0·90 1166 1415 0·82 9·5% (0·3 to 17·8) 0 0·044 8·0% (–1·7 to 16·7) ?? Ifakara8
Potential rebound period II***
Clinical malaria 
(primary deﬁnition)
1491 1368 1·09 1502 1370 1·10 –1·0% (–11·9 to 8·7) 18 0·843 –3·9% (–13·9 to 5·2) ?? Ifakara8
All-cause hospital 
admissions
404 1408 0·29 413 1470 0·28 –2·7% (–20·2 to 12·1) 0 0·735 –6·6% (–25·9 to 9·6) ?? Tamale12
Hospital admissions 
associated with malaria 
parasitaemia
105 1308 0·08 124 1302 1·0 –20·2% (–59·3 to 9·3) 0 0·199 –28·2% (–74·7 to 6·0) ?? Ifakara8
Anaemia (reduced risk 
of ﬁrst or only episode)
531 3839 0·14 522 3821 0·14 2·1% (–8·0 to 11·2) 0 0·673 0·9% (–9·5 to 10·2) ?? Ifakara8
PYAR=person-years at risk. IPT=intermittent preventive treatment. *Apart from anaemia, where the total number of children at risk is presented. †Protective eﬃcacy deﬁned as (1–RR)×100. ‡Proportion of the 
variation attributable to heterogeneity is presented as I2. §The sensitivity analysis removes the trial with the highest protective eﬃcacy from table 3. ¶Primary deﬁnition: history of fever or measured fever with 
any P falciparum parasitaemia. History of fever included reported fever during the past 24 h in the trials in Ifakara and Manhiça, and during the past 48 h for the other four trials. Measured fever was deﬁned as an 
axillary temperature 37·5°C or more for the trials in Ifakara, Navrongo, Tamale, and Manhiça; rectal or tympanic temperature 38°C or more for the trial in Kumasi, and 38·5°C or more for the trial in Lambaréné. 
||A history of fever, or measured fever, with a minimum P falciparum parasite density for each site chosen to have a speciﬁcity of more than 90%; trials in Ifakara, Manhiça, and Kumasi more than 500 parasites per 
µL; trial in Lambaréné more than 600 parasites per µL; trial in Tamale more than 5000 parasites per µL; trial in Navrongo more than 8000 parasites per µL. **Episodes with a history of fever or measured fever 
with P falciparum parasitaemia more than 20 000 parasites per µL. ††Admissions to a paediatric ward with any P falciparum parasitaemia irrespective of symptoms suggestive of malaria or a clinical diagnosis of 
malaria. ‡‡Packed-cell volume less than 25% in trials in Ifakara, Navrongo, and Manhiça and a haemoglobin concentration less than 80 g/L in trials in Kumasi, Lambaréné, and Tamale. §§For deﬁnitions see 
table 2. ¶¶From 35 days after dose at 3 months or 4 months of age until dose at 9 months of age. ||||From 35 days after the dose at 9 months of age up to the next dose of IPT or age 15 months. ***5-month 
period starting 35 days after last dose. [A: please check all footnotes are cited correctly] [A: incidence has been added, so that readers can compare IPT and placebo more easily. Please check that these 
ﬁgures are correct] [A: please check p values added and provide the missing values]
Table 4: Combined estimates and sensitivity analysis|
For more on the pooled analysis 
at 3 months after the last dose 
given see http://www.ipti-
malaria.org
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of Stevens–Johnson syndrome in the placebo group of 
the trial in Kumasi. Two further possible cases of this 
syndrome have also been reported in children from the 
same site, after they received a third dose of IPT [A: please 
conﬁrm they were in the IPT group and not the placebo 
group] at 15 months of age.11 Both children recovered 
without admission to hospital and presented to the study 
team in the convalescent phase. The study team erred on 
the side of caution and reported suspected Stevens–
Johnson syndrome, although the diagnosis has not been 
conﬁrmed (May J, personal communication). After a 
review of the existing information, reports, and a 
photograph of one of the cases, the consortium safety 
panel judged these two cases as unlikely to be 
Stevens–Johnson syndrome. IPT data, including the 
pooled analyses for safety and eﬃcacy, were reviewed by 
a panel of experts convened by the US Institute of 
Medicine. The experts also concluded that these cases 
were highly unlikely to be Stevens–Johnson syndrome,30 
because the syndrome is a severe disorder that requires 
intensive care, is associated with a high case-fatality rate, 
and a patient with the syndrome who is not admitted to 
hospital in a rural African setting is unlikely to recover.
Large-scale implementation studies of IPT with 
sulfadoxine-pyrimethamine in infants are being done by 
the IPTi Consortium in Tanzania and by UNICEF in six 
other African countries [A: are there references for 
these?]. Across these studies, more than 250 000 infants a 
year are receiving three doses of IPT alongside routine 
vaccination delivered by the EPI. So far, no serious 
adverse events related to IPT have been reported to the 
consortium safety panel (Schellenberg D, unpublished 
data; de Sousa A, [A: aﬃliation?], personal 
communication). Data obtained in the trials in Manhiça 
and Navrongo suggest that IPT with sulfadoxine-
pyrimethamine has no adverse eﬀect on serological 
responses to vaccines for polio, hepatitis B, measles, or 
diphtheria, tetanus, and pertussis (DTP),9,10 and there are 
reassuring data on yellow fever vaccination [A: what do 
you mean here—there is less convincing evidence for 
yellow fever vaccines, or that the evidence is from the 
following report? Please rephrase to clarify] (Interim 
report on IPTi with SP, WHO Advisory Committee on 
serological responses to EPI vaccines in infants receiving 
IPTi, WHO Internal Report 2006 [A: is this report in the 
public domain? If so, we would prefer to add to the 
reference list]).
The individual trials reported diﬀerent ﬁndings for 
various extended follow-up periods after the last dose of 
IPT or placebo. Sustained protection against clinical 
malaria was seen up to the age of 2 years in children 
assigned to IPT in the trial in Ifakara.31 In children aged 
between 16 months and 24 months in Navrongo, 
incidence of clinical malaria with a parasite density more 
than 5000 per µL was higher in the IPT group than in the 
placebo group. In the trial in Kumasi, the number of 
episodes of anaemia (haemoglobin <75 g/L) during the 
8-month period starting 5 weeks after the last dose at 
15 months of age was higher in the ITP group than in the 
placebo group; however, this diﬀerence was not seen 
with deﬁnitions of anaemia of haemoglobin 70 g/L or 
80 g/L. In the trial in Tamale, the risk of severe malarial 
anaemia (haemoglobin <50 g/L) during the 8-month 
period starting 1 month after the last IPT dose at 
15 months of age in children assigned to IPT was about 
double the risk in children assigned to placebo. There 
was no evidence of either sustained protection or of 
increased risk during extended follow-up in the trials in 
Lambaréné and Manhiça. [A: this section is a little 
diﬃcult to read and understand. Can you rephrase or 
present the results in a diﬀerent way?]
Even though ﬁndings have not been consistent across 
diﬀerent endpoints within or between trials, they have 
raised concerns that IPT in infants might impair the 
development of naturally acquired immunity to malaria. 
IPT Placebo
Events Number of events 
possibly related to 
treatment
Events Number of events 
possibly related to 
treatment
Deaths (number of deaths/number of infants [%]) [A1]
Ifakara8 5/350 (0·9%) 0 10/351 (2·8%) 0
Navrongo9* 22/1221 (1·8%) 0 11/1225 (0·9%) 0
Manhiça10 20/748 (2·7%) 0 22/755 (2·9%) 0
Kumasi11 3/535 (0·6%) 1 3/535 (0·6%) 0
Tamale12 6/600 (1·0%) 0 7/599 (1·2%) 0
Lambaréné13 0/504 (0%) 0 0/507 (0%) 0
Total 56/3958 (1·4%) 1 53/3972 (1·3%) 0
Non-fatal hospital admissions (number of admissions/PYAR [incidence per PYAR])
Ifakara8 106/248 (0·43) 0 151/251 (0·60) 0
Navrongo9* 248/874 (0·28) 0 309/867 (0·26) 0
Manhiça10 227/495 (0·46) 0 279/487 (0·57) 0
Kumasi11† 46/386 (0·12) 1 52/389[A3] (0·13) 2
Tamale12 23/402 (0·06) 1 52/401 (0·13) 1
Lambaréné13 26/327 (0·08) 2 17/330 (0·05) 2
Total [A2] 676 4 860 5
Serious dermatological adverse events (number of events/PYAR [incidence per PYAR])
Ifakara8 0/248 0 0/251 0
Navrongo9* ·· ··
Manhiça10 2/495 (0·004) 0 7/487 (0·01) 0
Kumasi11 0/386 0 2/398 [A3] (0·005) 1
Tamale12 0/402 0 2/401 (0·005) 0
Lambaréné13 1/327 (0·003) 0 2/330 (0·006) 0
Total [A2] 3 0 13 1
IPT=intermittent preventive treatment. PYAR=person-years at risk. ··=data not available. *In the trial in Navrongo, 
no deaths or serious dermatological adverse events were judged related to treatment, but no more details are 
available. †In the trial in Kumasi, three hospital admissions in the sulfadoxine-pyrimethamine group and two in the 
placebo group were not assessable to work out causality. [A1: percentages and incidences have been added, so that 
readers can compare IPT and placebo more easily. Please check that these ﬁgures are correct] [A2: why is the 
denominator not present?] [A3: person-years at risk diﬀer in this trial (389 for hospital admissions, 398 for 
SAEs), which is correct?]
Table 5: Deaths, non-fatal hospital admissions, and serious dermatological adverse events up to 
12 months of age, or 3 months after the last dose of study treatment received, whichever is earlier
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In the 5-month period starting 35 days after the last dose 
(ie, after treatment completion), [A: correct?] the incidence 
of hospital admissions associated with malaria 
parasitaemia was higher in the IPT group than in the 
placebo group; however, the pooled eﬀect estimate did 
not reach statistical signiﬁcance and there were no 
signiﬁcant increases in incidence of clinical malaria or 
all-cause hospital admissions, or in risk of anaemia 
during this period. These ﬁndings contrast with the 
protective eﬀect seen against these endpoints during the 
intervention period and, thus, the balance of risks and 
beneﬁts seem to favour IPT. Nevertheless, monitoring of 
morbidity should be part of studies of eﬀectiveness and 
phase IV studies in which IPT in infants is implemented. 
A pooled analysis for a possible rebound eﬀect was done 
for those trials with  extended follow-up periods (Ifakara, 
Manhiça, Lambaréné, and Navrongo); outcomes did not 
diﬀer between IPT and placebo groups in the 11-month 
period starting 35 days after the last dose (data not 
shown).
The ﬁrst trial of IPT in infants, undertaken in Ifakara, 
showed high protective eﬃcacy of the intervention. 
Because of these results, additional trials were done; 
however, they reported lower estimates of protective 
eﬃcacy. Protective eﬃcacy against clinical malaria was 
similar between trials during all periods analysed, apart 
from during the inter-dose period, when eﬃcacy was 
higher in the trial in Ifakara than in the other trials. 
Because of the diﬀerences in trial design between the six 
studies, we were unable to draw conclusions about the 
conditions under which IPT in infants might have the 
best possible eﬀect. However, a detailed comparison 
between very similar trials in Ifakara and Manhiça32 
suggested that the combined use of insecticide-treated 
bednets and IPT might explain the higher eﬃcacy 
reported in the Ifakara trial. Nevertheless, when 
sulfadoxine-pyrimethamine and artesunate were 
coadministered as IPT in a trial in western Kenya, where 
use of insecticide-treated bednets was very high, eﬃcacy 
[A: against clinical malaria?] was less than 30% 
(Newman R, Slutsker L, unpublished data).
Parasite resistance to sulfadoxine-pyrimethamine has 
spread across Africa, which could undermine the eﬃcacy 
of IPT in infants. The highest reported frequency of 
resistance during the trials was 31% (as measured by the 
WHO standard day 14 in-vivo clinical and parasitological 
resistance in 6–59-month-old symptomatic children). 
This level of resistance, which corresponds with 
intermediate levels as deﬁned by ter Kuile and 
colleagues,33 did not preclude protective eﬃcacy when 
sulfadoxine-pyrimethamine was used for IPT in infants. 
Furthermore, the site with the highest level of resistance 
to the drug combination (Ifakara)34 had the highest 
eﬃcacy of IPT, and in all trials (apart from in Lambaréné 
and after the last dose of IPT in Kumasi), there was 
signiﬁcant protection in the month after an IPT dose. 
These ﬁndings call into question the value of estimates 
of curative eﬃcacy to inform the use of antimalarial 
drugs for prevention where infections might be of low 
density and asymptomatic [A: meaning of highlighted 
sentence unclear; please rephrase]. Moreover, the 
increasing use of artemisinin-based combination therapy 
will lead to a reduction in the use of sulfadoxine-
pyrimethamine, reducing the spread of resistance and 
prolonging the duration for which this drug combination 
could be useful for IPT. A corresponding concern is that 
IPT with sulfadoxine-pyrimethamine in infants might 
facilitate the spread of drug resistance. Although the 
prevalence of markers of resistance to sulfadoxine-
pyrimethamine increases after doses in infants,35,36 
mathematical models suggest that the size of such eﬀect 
in the global spread of resistance will be small.37 At 
present, sulfadoxine-pyrimethamine is the only 
antimalarial drug available for IPT in both pregnancy 
and infancy, in view of the combination’s long half-life 
and prophylactic eﬀect, established safety proﬁle, 
acceptability,7,38 and aﬀordability. IPT seems to work by 
prophylaxis, with sulfadoxine-pyrimethamine providing 
protection for up to 6 weeks in infants.39,40 New long-
acting antimalarial drugs are urgently needed for use in 
IPT in infants.
Where malaria transmission is highly seasonal and 
severe malaria occurs rarely in infants, methods for 
delivering IPT to older children might be needed.41 
However, in areas with a substantial burden of malaria in 
infants, delivery of IPT through WHO’s EPI system has 
been shown to be highly cost eﬀective.42
[A: please provide a brief paragraph discussing the 
limitations of your analysis] 
This pooled analysis substantiates the notion that IPT 
is safe and eﬃcacious in infants. Furthermore, operational 
experience from Tanzania43 and six other African 
countries [A: reference?] shows that rapid large-scale 
deployment of IPT is feasible. Thus, this intervention 
For the pooled analysis of the 
extended follow-up period see 
http://www.ipti-malaria.org
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Figure 3: Combined estimates for the protective eﬃcacy of IPT with sulfadoxine-pyrimethamine in infants 
against clinical malaria from 35 days after the dose at 9 months of age until next dose or 15 months of age
The width of the diamond represents the 95% CI interval in the overall pooled protective eﬃcacy estimate. 
[A: vertical line moved to 0%. Ok?]
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could make an important contribution to reducing the 
intolerable burden of malaria in infants and should be 
integrated with other eﬀective control methods.32,44–50
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